Also known as ENTYVIO.
Treating to corticosteroid-free disease clearance with vedolizumab lengthened time to first ulcerative colitis complication and cut complication risk by about 70%.
FDA accepted an sBLA to extend IV vedolizumab (ENTYVIO) to children aged 2+ with moderately to severely active UC and Crohn’s; PDUFA Q1 2027.
Vedolizumab shows promise in treating pediatric ulcerative colitis, achieving 47.3% remission at 54 weeks, with a safety profile consistent with adult use.
The partnership aims to enhance vedolizumab delivery for IBD treatment, improving patient care and expanding access with ENHANZE technology.
